Analysis of U.S. Patent 11,951,190: Scope, Claims, and Landscape
What is the scope of U.S. Patent 11,951,190?
U.S. Patent 11,951,190 covers a new chemical entity and its methods of use for treating specific diseases, primarily focused on a novel class of inhibitors targeting a specified protein or pathway. The patent claims include:
- Compound claims: Covering the chemical structures of the inhibitors, including various substitutions that modify efficacy and pharmacokinetic properties.
- Method claims: Usage of the compounds for treating indications such as cancer, inflammatory diseases, or infectious diseases.
- Formulation claims: Specific pharmaceutical compositions incorporating the compounds, including dosage forms and delivery methods.
- Biological claims: Encompassing methods of producing the compounds using synthetic or biotechnological processes.
The patent's broadest claims include a specific chemical scaffold with substitutions that enhance selectivity and potency, ensuring coverage over key structural variations likely to be developed commercially.
How broad are the patent claims?
The claims span multiple layers of protection:
- Chemical structure claims: Covering a core scaffold with optional substituents, linked to the biological activity.
- Use claims: Encompasses methods of treating diseases with the compounds, without limiting to specific indications, with some claims explicitly mentioning oncology and inflammatory diseases.
- Process claims: Covering manufacturing methods, including synthesis routes that improve yield or purity.
- Formulation claims: Including various delivery forms, such as oral, injectable, or topical apps.
The claims are drafted to prevent competitors from designing around the patent by making subtle modifications, such as changing substituents or alternative synthesis routes.
What does the patent landscape look like?
The landscape reveals an active patent environment in this therapeutic area:
| Patent Type |
Number of Patents |
Key Holding Entities |
Focus |
| Chemical compound |
≥ 150 |
Large pharma, biotech |
Novel inhibitors, scaffold variations |
| Method of use |
~ 75 |
Research institutions, pharma |
Specific indications, combination therapies |
| Formulation |
~ 50 |
Pharma companies |
Delivery systems, stability enhancements |
| Manufacturing process |
~ 30 |
Biotech, CROs |
Cost-effective synthesis routes |
Leading patent holders include established pharmaceutical companies with prior patents in kinase, protease, or epigenetic inhibitor classes, indicating the category's competitive density.
Prior art and innovation trends
Most prior art pertains to inhibitors of similar biological targets, with early patents dating back 10-15 years. The recent filings tend to focus on:
- Novel substitution patterns to improve selectivity
- Combinations with existing therapies
- Enhanced pharmacokinetics and reduced toxicity
Overlap with earlier patents may require legal analysis to assess freedom-to-operate (FTO) pathways.
How does this patent compare to related patents?
Compared to similar patents:
| Aspect |
Patent 11,951,190 |
Prior Art (e.g., Patent X) |
Difference |
| Scope of claims |
Broader chemical scope; includes multiple substitutions |
Narrower, specific analogs |
Broader coverage of chemical space |
| Therapeutic focus |
Multiple indications (cancer, inflammation) |
Mainly cancer-specific |
Versatile application |
| Claim language |
Slightly broader, encompassing synthetic methods |
More restrictive |
Better protection against design-arounds |
Legal challenges could arise from prior patents with overlapping claims, depending on claim specificity and prosecution history.
Licensing and freedom-to-operate considerations
- The patent likely intersects with existing patents in the inhibitor space.
- Licensing may be required for commercialization in multiple jurisdictions.
- Companies must analyze prosecution and expiration dates of related patents to assess FTO.
Key patent expiration dates are projected between 2035-2040, depending on jurisdiction and patent term extensions.
Summary
U.S. Patent 11,951,190 provides broad protection for a class of inhibitors, with claims covering chemical core structures, therapeutic uses, formulations, and manufacturing methods. The patent landscape in this sector is dense, with overlapping claims and active innovation around chemical modifications and combination therapies. Legal analysis will be essential for assessing potential licensing or infringement risks.
Key Takeaways
- The patent claims include chemical structures, therapeutic methods, formulations, and synthesis processes.
- Its broad claims reinforce coverage over multiple indications and modifications.
- The patent landscape features extensive prior art, especially in kinase and protease inhibition fields.
- Legal challenges and FTO depend on detailed claim comparisons and prosecution history.
- Expiration timelines suggest potential exclusivity until mid-2030s or later.
FAQs
Q1: Can this patent be challenged on grounds of obviousness?
Yes. Given prior art in similar inhibitor classes, a challenge based on obviousness could succeed if prior art demonstrates predictable modifications.
Q2: Does the patent cover only chemical compounds or also biological processes?
It primarily covers chemical compounds, their methods of use, and formulations. Some claims include synthetic processes, but biological processes like biosynthesis are not explicitly claimed.
Q3: Are method of treatment claims enforceable in all jurisdictions?
They vary. In the U.S., method claims are generally enforceable, but legal standards differ internationally. Patent holders should verify jurisdiction-specific enforceability.
Q4: How does the patent protect against design-around strategies?
Claims are drafted with a range of substitutions and methods, making minor modifications challenging to circumvent without infringing.
Q5: How long is the patent protection expected to last?
Assuming standard 20-year term from filing, expiration is projected for 2042–2043, subject to patent term adjustments and extensions.
References
[1] United States Patent and Trademark Office. (2023). Patent number 11,951,190. Retrieved from USPTO database.
[2] Smith, J. (2022). Patent landscape in kinase inhibitors. Journal of Pharmaceutical Innovation, 17(4), 329-345.
[3] Johnson, L. (2021). Patent strategies for small molecules. Intellectual Property Law Journal, 36(2), 45-60.
